Non ST-elevation myocardial infarction: New Zealand management guidelines.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000698:Analgesia / Q000592:standards; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002309:Cardiology / Q000592:standards*; D017023:Coronary Angiography / Q000592:standards; D004562:Electrocardiography; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007249:Inflammation / Q000378:metabolism; D009203:Myocardial Infarction / Q000175:diagnosis* / Q000378:metabolism / Q000628:therapy*; D009204:Myocardial Revascularization / Q000592:standards; D045265:Natriuretic Peptides / Q000378:metabolism; D009520:New Zealand; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D018570:Risk Assessment / Q000379:methods; D014336:Troponin / Q000097:blood
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D015415:Biomarkers; D002121:Calcium Channel Blockers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D045265:Natriuretic Peptides; D010975:Platelet Aggregation Inhibitors; D014336:Troponin